Tickbird
Back to the track record

Tue, Oct 20, 2026 session

Today's pick

High conviction

GMAB

Genmab A/S

3 of 3 AIs said yes
Consensus score75.5
Confidence71.7
Post on XPost to Reddit

What the AIs concluded

The near-term bias is bullish because strong DARZALEX sales and positive oncology trial results provide fresh fundamental support. However, the recent rally and conflicting analyst estimates create a meaningful risk of volatility or profit-taking in the next U.S. session.

Catalysts

  • October 20, 2026: Genmab drew attention after reporting third-quarter DARZALEX net trade sales of approximately $4.239 billion, supporting royalty income.
  • Recent Phase 3 data for epcoritamab (EPKINLY) plus R-CHOP showed a statistically significant progression-free-survival benefit and a 51% reduction in the risk of progression or death in newly diagnosed diffuse large B-cell lymphoma.
  • Strong DARZALEX sales boost royalty income and highlight commercial strength.
  • Positive Phase 3 and Phase 2 trial results support future growth in oncology.
  • Phase 3 trial for EPKINLY showed a 51% reduction in disease progression risk in a common type of blood cancer, a major clinical win.

Risks flagged

  • The stock has already risen strongly, increasing the risk of profit-taking or a sell-the-news reaction.
  • Genmab remains heavily reliant on DARZALEX royalty income, while future sales erosion and pipeline execution are significant risks.
  • Recent rally could lead to profit-taking or short-term volatility.
  • Conflicting analyst estimates may create uncertainty.
  • The stock is already up about 11% over the past month, so some investors may take profits rather than push it higher.

The bar we set that morning

These thresholds were fixed before the analysis ran and are sealed into the fingerprint below, so they cannot be softened after the fact to make a call look better.

Score required
70.0 (68.0 base, raised 2 for a mixed market)
Confidence required
62%

Publication fingerprint

This analysis is sealed with a SHA-256 fingerprint computed the moment it was published. Any later edit would break it, which is what stops us from quietly rewriting history.

f7524725fc02efabafd5dcb11b28431339b5142fb6ce544db9933cc5dbf07d5c

Produced by algorithm v0.6.0, which is sealed inside the record above. If a newer version is running today, this call still names the rules it was actually made under — see the version history.

Do not take our word for it. The exact bytes that were sealed are public, so you can recompute the fingerprint yourself and compare:

curl -s https://tickbird.ai/api/public/signals/9cb18bf7-2cf5-4ade-b53e-00f01bcd804c/snapshot | sha256sum

On macOS, use shasum -a 256 instead.

Save that file today and run the same command in a year. If we had quietly edited a single character, the two fingerprints would no longer agree.

Open the sealed record

Anchored in Bitcoin

A fingerprint on our own server only proves the record still matches the number we published. It cannot prove the number is the original one, because we run the server. So the fingerprint is also submitted to OpenTimestamps, which writes it into the Bitcoin blockchain — a ledger nobody here controls.

Attested by Bitcoin block 972321. That block proves this analysis existed, word for word, before it was mined.

Check it yourself with the reference client, which talks to Bitcoin rather than to us:

pip install opentimestamps-client
curl -s https://tickbird.ai/api/public/signals/9cb18bf7-2cf5-4ade-b53e-00f01bcd804c/snapshot -o snapshot.json
curl -s https://tickbird.ai/api/public/signals/9cb18bf7-2cf5-4ade-b53e-00f01bcd804c/snapshot.ots -o snapshot.json.ots
ots verify snapshot.json.ots

The date it attests is when the fingerprint was submitted, which for older analyses can be later than the session itself.

This is not investment advice. Tickbird is an automated experiment. It publishes a general analysis, not a personal recommendation, and it makes no promise about any outcome. Past results do not predict future ones. Never risk money you cannot afford to lose.